Search Results

Stoke Therapeutics, Inc. today announced that management will present at the following upcoming investor conferences.

Stoke Therapeutics, Inc. today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer.

Stoke Therapeutics, Inc. today announced the appointment of Jason Hoitt as Chief Commercial Officer.

Stoke Therapeutics, Inc. reported financial results for the first quarter of 2024 and provided business updates including those related to STK-001, the Company’s proprietary antisense oligonucleotide which is in development by Stoke as the first potential medicine to address the genetic cause of Dravet syndrome.

Stoke Therapeutics, Inc. announced that, effective on June 17, 2024, the company granted stock options to purchase an aggregate of 10,400 shares of common stock to one new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635.

Stoke Therapeutics, Inc. announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to $75 million of shares of its common stock.

Stoke Therapeutics reported results for Dravet syndrome studies showing clinically meaningful effects, including reductions in convulsive seizure frequency, supporting the potential for disease modification.

Stoke Therapeutics, Inc. announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2023.

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the 23rd Annual Needham Virtual Healthcare Conference on Wednesday, April 10, 2024, at 10:15 a.m. ET.